JP MORGAN/PUT/BOSTON SCIENTIFIC/50/0.1/17.01.25 | Real-time Bid/Ask 11:35:12 21/06/2024 BST | ||
| 0.089 EUR / 0.15 EUR | +33.33% |
|
| Current month | -18.18% | ||
| 1 month | -18.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 0.087 | -3.33% |
| 20/06/24 | 0.09 | -3.23% |
| 19/06/24 | 0.093 | -7.00% |
| 18/06/24 | 0.1 | +8.70% |
| 17/06/24 | 0.092 | -7.07% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 07:59 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JL03GU |
| ISIN | DE000JL03GU2 |
| Date issued | 05/04/2023 |
| Strike | 50 $ |
| Maturity | 17/01/2025 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 0.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.81 € |
|---|---|
| Lowest since issue | 0.085 € |
| Spread | 0.061 € |
| Spread % | 40.67% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
77
USD
Average target price
82.26
USD
Spread / Average Target
+6.83%
- Stock Market
- Warrants
- Warrant
